These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26722766)

  • 41. Zoledronic acid and atrial fibrillation in cancer patients.
    Arslan C; Aksoy S; Dizdar O; Dede DS; Harputluoglu H; Altundag K
    Support Care Cancer; 2011 Mar; 19(3):425-30. PubMed ID: 20358384
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Short-term outcomes of neoadjuvant hormonal therapy versus neoadjuvant chemotherapy in breast cancer: systematic review and meta-analysis of randomized controlled trials.
    Huang L; Xu AM
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):327-334. PubMed ID: 28271747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.
    Coleman RE; Winter MC; Cameron D; Bell R; Dodwell D; Keane MM; Gil M; Ritchie D; Passos-Coelho JL; Wheatley D; Burkinshaw R; Marshall SJ; Thorpe H;
    Br J Cancer; 2010 Mar; 102(7):1099-105. PubMed ID: 20234364
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy: A Review of the Evidence.
    Chapman CH; Jagsi R
    Oncology (Williston Park); 2015 Sep; 29(9):657-66. PubMed ID: 26384802
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.
    Valachis A; Polyzos NP; Coleman RE; Gnant M; Eidtmann H; Brufsky AM; Aft R; Tevaarwerk AJ; Swenson K; Lind P; Mauri D
    Oncologist; 2013; 18(4):353-61. PubMed ID: 23404816
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effects of zoledronic acid in the treatment of breast cancer].
    Chen J; Liu ZY; Zhao LJ
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):318-9. PubMed ID: 21575510
    [No Abstract]   [Full Text] [Related]  

  • 49. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
    Miyazaki H; Nishimatsu H; Kume H; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Ishikawa A; Igawa Y; Hirano Y; Homma Y
    BJU Int; 2012 Dec; 110(11 Pt B):E520-5. PubMed ID: 22578070
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
    Safra T; Bernstein-Molho R; Greenberg J; Pelles-Avraham S; Stephansky I; Sarid D; Inbar MJ; Stemmer SM; Geffen DB
    Oncology; 2011; 81(5-6):298-305. PubMed ID: 22156381
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
    Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
    J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
    Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
    Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dosing of zoledronic acid throughout the treatment continuum in breast cancer.
    Hadji P; Gnant M; Aapro M; Lipton A; Coleman R
    Crit Rev Oncol Hematol; 2011 Aug; 79(2):175-88. PubMed ID: 20846875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
    George S; Weber DR; Kaplan P; Hummel K; Monk HM; Levine MA
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4163-71. PubMed ID: 26308295
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neoadjuvant dose-dense chemotherapy for locally advanced breast cancer: a meta-analysis of published studies.
    Petrelli F; Coinu A; Lonati V; Cabiddu M; Ghilardi M; Borgonovo K; Barni S
    Anticancer Drugs; 2016 Aug; 27(7):702-8. PubMed ID: 27058707
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting.
    Santini D; Virzi V; Fratto ME; Bertoldo F; Sabbatini R; Berardi R; Calipari N; Ottaviani D; Ibrahim T
    Curr Cancer Drug Targets; 2010 Feb; 10(1):46-54. PubMed ID: 20088792
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bisphosphonates and breast cancer incidence and recurrence.
    Chlebowski RT; Col N
    Breast Dis; 2011; 33(2):93-101. PubMed ID: 22142660
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
    Lancet; 2015 Oct; 386(10001):1353-1361. PubMed ID: 26211824
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.